Analogues of GLP-1

Details Analogues of GLP-1 Analogues of GLP-1

2011-03-01

2011-03-01

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000, C530S308000, C514S021300

Reexamination Certificate

active

07897566

ABSTRACT:
Disclosed are peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, methods of using such analogues to treat mammals and pharmaceutical compositions useful therefor comprising said analogues.

REFERENCES:
patent: 5512549 (1996-04-01), Chen et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5705483 (1998-01-01), Galloway et al.
patent: 6410513 (2002-06-01), Galloway et al.
patent: 6458924 (2002-10-01), Knudsen et al.
patent: 6620910 (2003-09-01), Calas et al.
patent: 6720407 (2004-04-01), Hughes et al.
patent: 6903186 (2005-06-01), Dong et al.
patent: 2003/0186858 (2003-10-01), Arentsen
patent: 2003/0220243 (2003-11-01), Glaesner et al.
patent: 0 733 644 (1993-09-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 699 686 (1996-03-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 869 135 (1998-10-01), None
patent: 87/06941 (1987-11-01), None
patent: 91/11457 (1991-08-01), None
patent: 97/29180 (1997-08-01), None
patent: 98/03547 (1998-01-01), None
patent: 98/08871 (1998-03-01), None
patent: 98/19698 (1998-05-01), None
patent: 99/43705 (1999-09-01), None
patent: 99/43706 (1999-09-01), None
patent: 99/43707 (1999-09-01), None
patent: 00/34331 (2000-06-01), None
patent: 00/34332 (2000-06-01), None
patent: 01/35988 (2001-05-01), None
patent: 01/57084 (2001-08-01), None
patent: 01/98331 (2001-12-01), None
patent: 2004/074315 (2004-09-01), None
Adelhorst, K. et al, “Structure-Activity Studies of Glucagon-Like Peptide-1”, 1994, J. of Biological Chem., 269:6275-6278.
Ahren, Bo, et al.; “Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus”; 1997; Journal of Clinical Endocrinology and Metabolism; 82:473-478.
Deacon, C.F., et al.; “Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity”; 1998; Diabetologia; 41:271-278.
Deacon, C.F., et al.; “Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig”; 1998; Diabetes; 47:764-769.
Gutniak, Mark, et al.; “Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus”; 1992; The New England Journal of Medicine; 326:1316-1322.
Mentlein, R., et al; “Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, Glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum”; 1993; Biochem; 214:829-835.
Mojsov, S. “Structural requirements for biological activity of glucagon-like peptide I,” Int. J. Pep. Prot. Res., 1992, 40:333-343.
Nauck, M.A. et al.; “Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIIDM”; 1996; Diabetologia; 82:1546-1553.
Parker, J. C. et al, “Structure-Function Analysis of a Series of Glucagon-Like Peptide-1 Analogs”, 1998, J. Peptide Res., 52:398-409.
Rachman, J. et al.; “Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM”; 1997; Diabetologia; 40:205-211.
Ritzel, U. et al, “A Synthetic Glucagon-Like Peptide-1 Analog With Improved Plasma Stability”, 1998, J. of Endocrinology, 159:93-102.
Suzuki, S., et al.; “Comparison of the Effects of Various C-Terminal and N-Terminal Fragment Peptides of Glucagon-Like Peptide-1 on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas”; 1989; Endocrinology; 125: 3109-3114.
Thorens, Bernard, et al.; “Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM”; 1993; Diabetes; 42:1219-1225.
Thorens, Bernard, et al.; “Structure and Function of the Glucagon-Like Peptide-1 Receptor”; 1996; Handbook of Experimental Pharmacology; 123:255-273.
Todd, J.F., et al.; “Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus”; 1997; European Journal of Clinical Investigation; 27:533-536.
Dong, J. Z. et al., “Glucagon-like peptide-1 analogs with significantly improved in vivo activity”, 2001, Peptides: The Wave of the Future, Michal Lebl and Richard Houghten, Eds., American Peptide Society, p. 670-671.

Affiliated with

Also associated with

Rating

Analogues of GLP-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Analogues of GLP-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogues of GLP-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2762426